The Cancer Letter

Inside information on cancer research and drug development

In Brief

Christina Coughlin named chief medical officer of Immunocore Ltd.

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

CHRISTINA COUGHLIN was named chief medical officer of Immunocore Ltd.

Most recently, Coughlin was leading two early development programs at Novartis in checkpoint inhibition and PI3 kinase inhibition. She led the overall program early development teams, including preclinical pharmacology, toxicology, clinical pharmacology, clinical development, biomarker development and regulatory work.

Before that, she served as international project team leader at Morphotek Inc., where she led the early clinical development team responsible for monoclonal antibody development against novel targets.

Table of Contents

YOU MAY BE INTERESTED IN

Conversation with The Cancer Letter

Infections are a major cause of death in patients treated with CAR T-cell therapy
Meta-analysis focused on causes of death, excluding relapse, recurrence

More than half of deaths that are not attributed to disease progression or recurrence after CAR T-cell therapy are caused by infections—an unprecedented finding that experts say marks a shift from a conventional focus on mitigating treatment-specific adverse events to including prevention and management of infections.
By Matthew Bin Han Ong
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account